Frontotemporal Dementia Clinical Trial
Official title:
A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Verified date | May 2024 |
Source | Alector Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A phase 3 double blind, placebo controlled study evaluating the efficacy and safety of AL001 in participants at risk for or with frontotemporal dementia due to heterozygous mutations in the progranulin gene.
Status | Active, not recruiting |
Enrollment | 110 |
Est. completion date | October 11, 2027 |
Est. primary completion date | September 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 25 Years to 85 Years |
Eligibility | Inclusion Criteria: - Persons with a progranulin gene mutation and at risk of developing FTD symptoms as evidenced by a biomarker, or persons with a progranulin gene mutation and diagnosed with FTD. - If symptomatic, one or more of the criteria for the diagnosis of possible behavioral variant FTD, or a diagnosis of Primary Progressive Aphasia. - Study partner who consents to study participation and who cares for/visits the participant daily for at least 5 hours per week. - Written informed consent must be obtained and documented (from the participant or, where jurisdictions allow it, from their legal decision maker). Exclusion Criteria: - Dementia due to a condition other than FTD including, but not limited to, Alzheimer's disease, Parkinson's disease, dementia with Lewy bodies, Huntington disease, or vascular dementia. - Known history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric, human, or humanized antibodies or fusion proteins. - Current uncontrolled hypertension, diabetes mellitus or thyroid disease. Clinically significant heart disease, liver disease or kidney disease. History or evidence of clinically significant brain disease other than FTD. - Females who are pregnant or breastfeeding, or planning to conceive within the study period. - Any experimental vaccine or gene therapy. - History of cancer within the last 5 years. - Current use of anticoagulant medications (e.g., coumadin, heparinoids, apixaban). - Residence in a skilled nursing facility, convalescent home, or long term care facility at screening; or requires continuous nursing care. |
Country | Name | City | State |
---|---|---|---|
Argentina | Fundación Para La Lucha Contra Las Enfermedades Neurológicas de La Infancia | Buenos Aires | |
Argentina | CENydET S.R.L. | Retiro | Ciudad Autónoma De BuenosAires |
Argentina | INECO Castaño | San Juan | |
Australia | Box Hill Hospital | Box Hill | |
Australia | Royal Prince Alfred Hospital | Camperdown | |
Australia | The Queen Elizabeth Hospital | Woodville | |
Belgium | UZ Leuven | Leuven | Vlaams Brabant |
Canada | The University of Western Ontario | London | |
Canada | Sunnybrook Research Institute - University of Toronto | Toronto | |
France | CHU de Bordeaux | Bordeaux | |
France | CHRU Lille | Lille | |
France | Groupe Hospitalier Pitié Salpétrière | Paris | |
France | Hopital Charles Nicolle - Hospital | Rouen | Seinne-Maritime |
France | CHU de Toulouse Hopital PURPAN | Toulouse | Haute-Garonne |
Germany | Uniklinik Köln | Köln | |
Germany | Universitätsklinikum Ulm | Ulm | |
Greece | University General Hospital of Alexandroupolis - Department of Neurology | Alexandroupoli | Evros |
Greece | Eginitio University General Hospital of Athens - 1st University Neurology Clinic | Athens | Attica |
Italy | Nuovo Ospedale Civile S. Agostino-Estense di Baggiovara | Baggiovara | |
Italy | IRCCS Istituto delle Scienze Neurologiche di Bologna | Bologna | |
Italy | ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia | Brescia | |
Italy | IRCCS - Centro S. Giovanni di Dio Fatebenefratelli | Brescia | |
Italy | Fondazione Istituto G.Giglio | Cefalù | Palermo |
Italy | Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico | Milano | |
Italy | Fondazione IRCCS Di Rilievo Nazionale Istituto Nazionale Neurologico Carlo Besta | Milano | |
Italy | Azienda Unita Sanita Locale (ASL) di Reggio Emilia - IRCCS | Reggio Emilia | Emilia Romagna |
Italy | PIA Fondazione Panico | Tricase | |
Netherlands | Erasmus MC | Rotterdam | |
Portugal | Centro Hospitalar E Universitário de Coimbra EPE | Coimbra | |
Portugal | Centro Hospitalar de Lisboa Norte, EPE - Hospital de Santa Maria | Lisboa | |
Portugal | Hospital CUF Descobertas | Lisboa | |
Portugal | Centro Hospitalar do Porto - Hospital de Santo António | Porto | |
Spain | Hospital Clinic de Barcelona | Barcelona | |
Spain | Hospital Universitario de Donostia | Donostia-san Sebastián | |
Spain | Hospital Clinico San Carlos | Madrid | |
Spain | Hospital Universitario de La Princesa | Madrid | |
Spain | Hospital Universitario Marques de Valdecilla | Santander | Cantabria |
Sweden | Karolinska Universitetssjukhuset Huddinge - PPDS | Huddinge | |
Switzerland | Felix Platter Spital | Basel | |
Turkey | Istanbul University Medical Faculty | Istanbul | Fatih |
Turkey | Dokuz Eylul University | Izmir | Balcova |
United Kingdom | University College London | London | |
United States | Emory University | Atlanta | Georgia |
United States | University of Colorado | Aurora | Colorado |
United States | Johns Hopkins University School of Medicine | Baltimore | Maryland |
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | University Of Cincinnati Gardner Neuroscience institute | Cincinnati | Ohio |
United States | Case Western Reserve University | Cleveland | Ohio |
United States | University of Kansas Alzheimer's Disease Center | Fairway | Kansas |
United States | Houston Methodist Institute for Academic Medicine | Houston | Texas |
United States | Indiana University Health Neuroscience Center | Indianapolis | Indiana |
United States | University of California San Diego | La Jolla | California |
United States | University of Miami Medical Center | Miami | Florida |
United States | Froedtert and The Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Irving Institute for Clinical and Translational Research | New York | New York |
United States | University of Pennsylvania | Philadelphia | Pennsylvania |
United States | Dignity Health | Phoenix | Arizona |
United States | Oregon Health and Science University | Portland | Oregon |
United States | Mayo Comprehensive Cancer Center - PPDS | Rochester | Minnesota |
United States | University of Texas Health Science Center at San Antonio | San Antonio | Texas |
Lead Sponsor | Collaborator |
---|---|
Alector Inc. |
United States, Argentina, Australia, Belgium, Canada, France, Germany, Greece, Italy, Netherlands, Portugal, Spain, Sweden, Switzerland, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Optional Open-Label Extension | Assess the long-term safety and tolerability of AL001 in participants who have completed 96 week of treatment | 96 weeks | |
Primary | Evaluation of efficacy of AL001 as measured by the CDR® plus NACC FTLD-SB | The Clinical Dementia Rating Dementia Staging Instrument PLUS National Alzheimer's Disease Coordinating Center frontotemporal lobar degeneration Behavior & Language Domains Sum of Boxes (CDR® plus NACC FTLD-SB) is administered by a healthcare professional and based on individual ratings of the eight domains: memory, orientation, judgment and problem solving, community affairs, home and hobbies, personal care, language and behavior. Impairment is scored on a scale in which none = 0, questionable = 0.5, mild = 1, moderate = 2 and severe = 3. The 8 individual domain ratings, or "box scores", were added together to give the CDR® plus NACC FTLD-SB which ranges from 0-24. Higher score indicates severe impairment. | Through study completion, on average up to 96 weeks | |
Secondary | Change in Clinical Global Impression-Severity (CGI-S) Score | The CGI-S is used by a clinician to rate the severity of a participant's disease relative to the clinician's past experience with patients who have the same disease using an ordinal scale ranging from 1=normal, not at all ill; 2=borderline ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; and 7=among the most extremely ill patients. Higher scores indicate worsening. | Baseline to 96 weeks | |
Secondary | Change in Clinical Global Impression-Improvement (CGI-I) Score | The CGI-I is used by a clinician to rate how much a participant's disease has improved or worsened relative to baseline using an ordinal scale ranging from 1=very much improved; 2=much improved; 3=minimally improved; 4=no change from baseline; 5=minimally worse; 6= much worse; and 7=very much worse. Higher scores indicate worsening. | Baseline to 96 weeks | |
Secondary | Change in Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Score | RBANS is 20 to 25 minute battery developed for cognitive assessment, detection, and characterization of dementia. RBANS includes 12 subtests that measure following 5 indices: (1)Attention Index, composed of Digit Span and Coding; (2)Language Index, consisting of Picture Naming and Semantic Fluency subtests; (3)Visuospatial/Construction Index, made up of Figure Copy and Line Orientation subtests; (4)Immediate Memory Index, composed of List Learning and Story Memory subtests, and (5)Delayed Memory Index, consisting of List Recall, List Recognition, Story Recall, and Figure Recall subtests. Completion of RBANS yields 5 index scores based on participant performance on various subtests, as well as a composite Total Index score for battery. Total index scores range from 40 to 160, and are normalized to a mean of 100 and standard deviation (SD) of 15. Higher scores indicate less impairment. | Baseline to 96 weeks | |
Secondary | Pharmacodynamic Biomarkers | Change in magnetic resonance imaging and blood-based biomarkers and optional CSF biomarkers (neurofilament light chain and progranulin) | Baseline to 96 weeks | |
Secondary | Evaluation of safety and tolerability of AL001: Incidence of adverse events | Incidence of adverse events | Baseline to 96 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05288842 -
Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
|
||
Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
Active, not recruiting |
NCT03987295 -
A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2)
|
Phase 2 | |
Withdrawn |
NCT05497817 -
A Study to Evaluate Caregiver Connections Via Technology for Patients With Alzheimer's and Other Types of Dementia
|
N/A | |
Recruiting |
NCT04918251 -
EEG and TMS-based Biomarkers of ALS, MS and FTD
|
||
Completed |
NCT01890343 -
Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls.
|
Phase 2 | |
Completed |
NCT01002300 -
Oxytocin and Social Cognition in Frontotemporal Dementia
|
N/A | |
Completed |
NCT00376051 -
Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia
|
Phase 4 | |
Terminated |
NCT00159198 -
Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
Phase 1 | |
Active, not recruiting |
NCT04516499 -
Neurofilament Surveillance Project (NSP)
|
||
Recruiting |
NCT04747431 -
A Study of PBFT02 in Patients With Frontotemporal Dementia and Progranulin Mutations (FTD-GRN)
|
Phase 1/Phase 2 | |
Completed |
NCT03636204 -
A First in Human Study in Healthy Volunteers and in Participants With Frontotemporal Dementia With Granulin (GRN) Mutation
|
Phase 1 | |
Completed |
NCT01937013 -
Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia
|
Phase 2 | |
Active, not recruiting |
NCT05075187 -
Epidemiological Study in FRONtoTemporal Dementia
|
||
Not yet recruiting |
NCT05004558 -
Effects of Remote-based Resistance Training on Cardiometabolic Risk Factors, Cognitive Function, and Quality of Life in Adults Living With Alzheimer's Disease and/or Related Dementias
|
N/A | |
Completed |
NCT02999282 -
Rehabilitative Trial for the Rescue of Neurophysiological Parameters in Progranulin Deficient Subjects
|
N/A | |
Completed |
NCT00594737 -
Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
|
Phase 3 | |
Recruiting |
NCT03225144 -
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
|
||
Active, not recruiting |
NCT04993755 -
A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD
|
Phase 2 | |
Recruiting |
NCT04114994 -
Longitudinal Cognitive Assessment by BoCA
|